Herpes Vaccine Development
HSV-1 gC-1 immunization may stimulate antibodies that modify disease
Published in Vaccine Weekly, October 26th, 2005
According to a study from the United States, "Herpes simplex virus type 1 (HSV-1) glycoprotein gC (gC-1) is an immune evasion molecule that inhibits complement activation by binding C3b. Three assays were used to assess whether IgG antibodies produced by HSV-1 infection in humans block the interaction between C3b and gC-1. In two assays human IgG had no effect, while in one assay IgG partially inhibited Ob binding, which occurred at IgG concentrations approaching the upper limits of those found in human serum."
"Mice infected with HSV-1 produced antibodies that...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2005-10-26)
More Articles from Vaccine Weekly
- HIV/AIDS Vaccine Development
Efficacy of recombinant glycoprotein 120 vaccine reported - Influenza Vaccine Development
Trivalent influenza vaccine safe in healthy children - Malaria Vaccine Development
P36p-deficient malarial sporozoites protect infected liver cells - Smallpox Vaccine
Clinical responses to smallpox vaccine examined - Allergy & Immunology
Frequency of antigen-specific CD4+ T cells affects allergic airway inflammation - Anthrax Vaccines
Reports advance knowledge in anthrax vaccines research - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
